Evrofarma Statistics

Total Valuation

Evrofarma has a market cap or net worth of EUR 24.00 million. The enterprise value is 40.67 million.

Market Cap	24.00M
Enterprise Value	40.67M

Important Dates

The next estimated earnings date is Monday, December 23, 2024.

Earnings Date	Dec 23, 2024
Ex-Dividend Date	Sep 12, 2024

Share Statistics

Evrofarma has 13.67 million shares outstanding. The number of shares has increased by 0.05% in one year.

Current Share Class	n/a
Shares Outstanding	13.67M
Shares Change (YoY)	+0.05%
Shares Change (QoQ)	-0.06%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	n/a

Valuation Ratios

The trailing PE ratio is 10.98.

PE Ratio	10.98
Forward PE	n/a
PS Ratio	0.51
PB Ratio	1.36
P/TBV Ratio	1.36
P/FCF Ratio	9.79
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.85, with an EV/FCF ratio of 16.59.

EV / Earnings	18.60
EV / Sales	0.87
EV / EBITDA	7.85
EV / EBIT	11.79
EV / FCF	16.59

Financial Position

The company has a current ratio of 1.38, with a Debt / Equity ratio of 0.97.

Current Ratio	1.38
Quick Ratio	0.73
Debt / Equity	0.97
Debt / EBITDA	3.33
Debt / FCF	6.99
Interest Coverage	2.61

Financial Efficiency

Return on equity (ROE) is 13.23% and return on invested capital (ROIC) is 5.83%.

Return on Equity (ROE)	13.23%
Return on Assets (ROA)	4.12%
Return on Capital (ROIC)	5.83%
Revenue Per Employee	282,193
Profits Per Employee	13,175
Employee Count	156
Asset Turnover	0.90
Inventory Turnover	4.37

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +55.31% in the last 52 weeks. The beta is 1.03, so Evrofarma's price volatility has been similar to the market average.

Beta (5Y)	1.03
52-Week Price Change	+55.31%
50-Day Moving Average	1.47
200-Day Moving Average	1.57
Relative Strength Index (RSI)	75.37
Average Volume (20 Days)	9,994

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Evrofarma had revenue of EUR 46.84 million and earned 2.19 million in profits. Earnings per share was 0.16.

Revenue	46.84M
Gross Profit	7.06M
Operating Income	3.42M
Pretax Income	2.76M
Net Income	2.19M
EBITDA	5.10M
EBIT	3.42M
Earnings Per Share (EPS)	0.16

Full Income Statement

Balance Sheet

The company has 470,000 in cash and 17.14 million in debt, giving a net cash position of -16.67 million or -1.22 per share.

Cash & Cash Equivalents	470,000
Total Debt	17.14M
Net Cash	-16.67M
Net Cash Per Share	-1.22
Equity (Book Value)	17.63M
Book Value Per Share	1.29
Working Capital	5.20M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 4.74 million and capital expenditures -2.29 million, giving a free cash flow of 2.45 million.

Operating Cash Flow	4.74M
Capital Expenditures	-2.29M
Free Cash Flow	2.45M
FCF Per Share	0.18

Full Cash Flow Statement

Margins

Gross margin is 15.08%, with operating and profit margins of 7.29% and 4.67%.

Gross Margin	15.08%
Operating Margin	7.29%
Pretax Margin	5.89%
Profit Margin	4.67%
EBITDA Margin	10.90%
EBIT Margin	7.29%
FCF Margin	5.23%

Dividends & Yields

This stock pays an annual dividend of 0.05, which amounts to a dividend yield of 2.85%.

Dividend Per Share	0.05
Dividend Yield	2.85%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.05%
Shareholder Yield	2.80%
Earnings Yield	9.11%
FCF Yield	10.21%

Dividend Details

Stock Splits

The last stock split was on July 26, 2001. It was a forward split with a ratio of 2.

Last Split Date	Jul 26, 2001
Split Type	Forward
Split Ratio	2

Scores

Evrofarma has an Altman Z-Score of 1.96. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.96
Piotroski F-Score	n/a